ALKS vs AZN

ALKS exhibits a weak Piotroski F-Score of 4/9, indicating marginal financial health, and lacks an Altman Z-Score, raising concerns about default risk. Despite a strong Graham Number of $18.80 and intrinsic value estimate of $10.01, the current price of $27.76 trades at a significant premium, especially given deteriorating growth and profitability metrics. The company shows a sharp decline in revenue and earnings (YoY: -10.6% and -67.0%), with recent quarterly earnings missing expectations and negative Q/Q trends. Insider selling activity over the past six months further undermines confidence, despite strong historical earnings surprises. The market appears to be pricing in future recovery, but current fundamentals suggest caution.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.